Clinical Trials
17 trialsNCT04969835 2026-05-15
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
Phase 1 Recruiting
NCT05408845 2026-05-04
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
Phase 2 Recruiting
NCT04620187 2026-04-13
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT05884320 2026-03-20
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03740256 2026-02-06
VISTA
Baylor College of Medicine
Phase 1 Recruiting
NCT05553782 2026-01-26
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Brigham and Women's Hospital
Phase EARLY_PHASE1 Recruiting
NCT03942653 2025-12-31
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT04452162 2025-09-09
PSGT
Abramson Cancer Center at Penn Medicine
Phase NA Recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06805617 2025-07-29
I-MAC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06923826 2025-07-25
TROP2
National University Hospital, Singapore
Phase 2 Recruiting
NCT04214366 2023-11-30
ACCO
Heidelberg University
Phase 2 Recruiting